Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effectiveness of GSK598809, a Selective D3 Antagonist, Added to Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation and Prevention of Very Early Relapse to Smoking

This study has been completed.
National Institute on Drug Abuse (NIDA)
Mclean Hospital
Information provided by (Responsible Party):
Maurizio Fava, MD, Massachusetts General Hospital Identifier:
First received: August 5, 2010
Last updated: September 16, 2014
Last verified: September 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2013
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)